ClinicalTrials.gg
CompletedNCT01456936EAGLESUpdated Jun 10, 2016Results posted

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

A Phase 4 interventional study of Placebo and varenicline tartrate in Smoking Cessation, sponsored by Pfizer. Completed at 156 sites in 16 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-10.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,144
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
Largest of 110
8,144 · median 209
Started
2011
with 10 others
Phase 4
47 of 110
3 open now
Registered
62nd of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one has the largest enrollment, is one of 11 that started in 2011, is one of 47 in phase 4, and was the 62nd registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these populations).

03

Conditions studied

  • Smoking Cessation

Keywords

  • smoking cessation
  • psychiatric disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female cigarette smokers, 18- 75 years, motivated to stop smoking and considered suitable for a smoking cessation attempt.
  • Smoked an average of at least 10 cigarettes per day during past year and during the month prior to the screening visit, and exhaled carbon monoxide (CO) >10 ppm at screening.
  • For Neuropsychiatric cohort- subjects must have proper diagnosis as outlined in protocol.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a past or current diagnosis of one of the following disorders:

    a. Psychotic Disorders:

  • Schizophreniform
  • Delusional Disorder
  • Psychotic Disorder NOS b. All Delirium, Dementia, and Amnestic and Other Cognitive Disorders c. All Substance Induced Disorders (Other than nicotine)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
8,144 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.

    Drug: Placebo

  • Active comparator
    varenicline

    Drug: varenicline tartrate

  • Active comparator
    bupropion

    Drug: bupropion hydrochloride

  • Active comparator
    Nicotine Replacement Therapy Patch

    Drug: Nicotine Replacement Therapy Patch

Interventions

  • DrugPlacebo

    Triple dummy placebo for each treatment arm

  • Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks

    Also known as: Chantix; Champix

  • Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).

  • DrugNicotine Replacement Therapy Patch

    Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.

    Also known as: NRT

06

What researchers measure

Primary outcomes

  1. Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint

    The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  2. Estimated NPS AE Rate (%), by Cohort

    The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

Secondary outcomes

  1. Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort

    The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  2. Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort

    The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  3. Occurrence of the Components of NPS AE Primary Endpoint (Overall)

    The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  4. Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort

    The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  5. Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort

    The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  6. Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort

    The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  7. Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)

    The NPS AE endpoint was the occurrence of at least 1 treatment-emergent "severe" AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent "severe" AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

    Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  8. Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort

    The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.

    Time frame: Baseline to Week 24

  9. HADS Total Score, Psychiatric History Cohort

    The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.

    Time frame: Baseline to Week 24

  10. HADS Total Score (Overall)

    The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.

    Time frame: Baseline to Week 24

  11. Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Non-psychiatric History Cohort

    The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.

    Time frame: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  12. Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Psychiatric History Cohort

    The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.

    Time frame: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  13. Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Overall

    The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.

    Time frame: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

  14. Clinical Global Impression of Improvement (CGI-I), "No Change" Rating by Visit

    The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as "normal, not at all ill" on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as "no change" on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.

    Time frame: Baseline to Week 24

  15. CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort

    A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).

    Time frame: Week 9 through Week 12

  16. CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort

    A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).

    Time frame: Week 9 through Week 12

  17. CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)

    A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).

    Time frame: Week 9 through Week 12

  18. CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort

    A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).

    Time frame: Week 9 through Week 24

  19. CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort

    A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).

    Time frame: Week 9 through Week 24

  20. CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)

    A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).

    Time frame: Week 9 through Week 24

  21. 7-Day Point Prevalence of Abstinence, Non-psychiatric History Cohort

    A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?

    Time frame: 24 Weeks

  22. 7-Day Point Prevalence of Abstinence, Psychiatric History Cohort

    A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?

    Time frame: 24 Weeks

  23. 7-Day Point Prevalence of Abstinence (Overall)

    A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?

    Time frame: 24 Weeks

07

Results

Posted May 2, 2016
Limitations and caveats
After database lock and unblinding, one additional participant in the NRT arm of psychiatric cohort was found who had a primary endpoint event (moderate suicidal ideation) which required hospitalization; this event is not included in any analyses.

Participant flow

A total of 11,186 participants were screened for participation in the study, of which 3042 participants were considered to be screen failures, leaving 8144 participants eligible for study participation (efficacy population). 86 participants (1.1%) did not receive study drug. A total of 8058 participants received study drug (safety population).

Participant flow — Overall Study
MilestoneVareniclineBupropionNRT PatchPlacebo
Started2037203420382035
Randomized and treated2016200620222014
Completed1598158615571552
Not completed439448481483
Withdrew: Other reason41303633
Withdrew: No longer meets eligibility criteria4865
Withdrew: Protocol violation4255
Withdrew: Pregnancy1001
Withdrew: Insufficient clinical response441413
Withdrew: No longer willing to participate195218224248
Withdrew: Lost to follow-up135126144127
Withdrew: Medication error0101
Withdrew: Adverse event (study drug)25212617
Withdrew: Adverse event (study drug unrelated)9799
Withdrew: Death0313
Withdrew: Randomized but not treated21281621

Outcome measures

PrimaryOccurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint

The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · percentage of participants
Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Non-psychiatric cohort (N= 990, 989, 1006, 999)1.32.22.52.4
Psychiatric cohort (N= 1026, 1017, 1016, 1015)6.56.75.24.9
Overall (N= 2016, 2006, 2022, 2014)4.04.53.93.7
Statistical analysis
  • Varenicline 1.0 mg BID vs Bupropion 150 mg BID vs NRT Patch vs Placebo · Regression, Linear · p = 0.0652 (An interaction between treatment and cohort was considered significant at 10% level. No multiplicity adjustments were utilized.)A generalized linear regression analysis based on the safety analysis set was used to evaluate incidence of NPS AE as the primary analysis.
PrimaryEstimated NPS AE Rate (%), by Cohort

The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Least squares mean · percentage of participants
Estimated NPS AE Rate (%), by Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Non-psychiatric cohort (N=3984)1.25 (0.60 to 1.90)2.44 (1.52 to 3.36)2.31 (1.37 to 3.25)2.52 (1.58 to 3.46)
Psychiatric cohort (N= 4074)6.42 (4.91 to 7.93)6.62 (5.09 to 8.15)5.20 (3.84 to 6.56)4.83 (3.51 to 6.16)
Statistical analysis
  • Varenicline 1.0 mg BID vs Placebo · Regression, Linear · Risk difference (rd): -1.28 · 95% CI -2.40 to -0.15Risk difference for varenicline versus placebo from estimation model.
  • Bupropion 150 mg BID vs Placebo · Regression, Linear · Risk difference (rd): -0.08 · 95% CI -1.37 to 1.21Risk difference for bupropion 150 mg BID versus placebo from estimation model.
  • NRT Patch vs Placebo · Regression, Linear · Risk difference (rd): -0.21 · 95% CI -1.54 to 1.12Risk difference for NRT versus placebo from estimation model.
  • Varenicline 1.0 mg BID vs Placebo · Regression, Linear · Risk difference (rd): 1.59 · 95% CI -0.42 to 3.59Risk difference for varenicline versus placebo from estimation model
  • Bupropion 150 mg BID vs Placebo · Regression, Linear · Risk difference (rd): 1.78 · 95% CI -0.24 to 3.81Risk difference for bupropion 150 mg BID versus placebo from estimation model.
  • NRT Patch vs Placebo · Regression, Linear · Risk difference (rd): 0.37 · 95% CI -1.53 to 2.26Risk difference for NRT versus placebo from estimation model.
SecondaryOccurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort

The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants
Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort
participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Anxiety (severe)0103
Depression (severe)1000
Feeling abnormal (severe only)0000
Hostility (severe)0110
Agitation (moderate and severe)10111911
Aggression (moderate and severe)3323
Delusions (moderate and severe)0010
Hallucinations (moderate and severe)1000
Mania (moderate and severe)0122
Panic (moderate and severe)0413
Paranoia (moderate and severe)0100
Psychosis (moderate and severe)0010
Homicidal ideation (moderate and severe)0010
Suicidal behavior (moderate and severe)0110
Suicidal ideation (moderate and severe)0123
Suicide (moderate and severe)0001
SecondaryOccurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort

The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants
Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort
participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Anxiety (severe)5462
Depression (severe)6476
Feeling abnormal (severe only)0100
Hostility (severe)0000
Agitation (moderate and severe)25292122
Aggression (moderate and severe)14978
Delusions (moderate and severe)1110
Hallucinations (moderate and severe)5422
Mania (moderate and severe)7936
Panic (moderate and severe)716137
Paranoia (moderate and severe)1002
Psychosis (moderate and severe)4231
Homicidal ideation (moderate and severe)0000
Suicidal behavior (moderate and severe)1101
Suicidal ideation (moderate and severe)5232
Suicide (moderate and severe)0000
SecondaryOccurrence of the Components of NPS AE Primary Endpoint (Overall)

The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants
Occurrence of the Components of NPS AE Primary Endpoint (Overall)
participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Anxiety5565
Depression7476
Feeling Abnormal0100
Hostility0110
Agitation35404033
Aggression1712911
Delusions1120
Hallucination6422
Mania71058
Panic Disorder7201410
Paranoia1102
Psychosis4241
Homicidal Ideation0010
Suicidal Behavior1211
Suicidal Ideation5355
Suicide0001
SecondaryOccurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort

The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · percentage of participants
Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Non-psychiatric cohort (N= 990, 989, 1006, 999)0.10.40.30.5
Psychiatric cohort (N= 1026, 1017, 1016, 1015)1.41.41.41.3
Overall (N= 2016, 2006, 2022, 2014)0.70.90.80.9
SecondaryOccurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort

The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants
Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort
participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Anxiety0103
Depression1000
Feeling abnormal0000
Hostility0110
Agitation0020
Aggression1100
Delusions0000
Hallucinations0000
Mania0000
Panic0111
Paranoia0000
Psychosis0000
Homicidal ideation0000
Suicidal behavior0100
Suicidal ideation0001
Suicide0001
SecondaryOccurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort

The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants
Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort
participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Anxiety5462
Depression6476
Feeling abnormal0100
Hostility0000
Agitation1142
Aggression1101
Delusions0000
Hallucinations0100
Mania2100
Panic0101
Paranoia0000
Psychosis0110
Homicidal ideation0000
Suicidal behavior1101
Suicidal ideation1010
Suicide0000
SecondaryOccurrence of the Components of Severe-only NPS AE Endpoint (Overall)

The NPS AE endpoint was the occurrence of at least 1 treatment-emergent "severe" AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent "severe" AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.

Time frame:
Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants
Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)
participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Anxiety5565
Depression7476
Feeling Abnormal0100
Hostility0110
Agitation1162
Aggression2201
Delusions0000
Hallucination0100
Mania2100
Panic Disorder0212
Paranoia1102
Psychosis4241
Suicidal Behavior1201
Suicidal Ideation1010
Suicide0001
Homicidal Ideation0010
SecondaryHospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort
Units on a scaleVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Week 1 (N= 984, 972, 989, 992)3.26 ± 3.923.58 ± 4.253.06 ± 3.873.38 ± 4.20
Week 2 (N= 961, 954, 963, 970)2.91 ± 3.863.07 ± 3.962.84 ± 3.853.20 ± 4.25
Week 3 (N= 935, 930, 936, 941)2.61 ± 3.852.64 ± 3.822.63 ± 3.932.77 ± 3.94
Week 4 (N= 923, 916, 934, 923)2.40 ± 3.662.36 ± 3.572.46 ± 3.802.77 ± 4.21
Week 5 (N= 911, 897, 906, 902)2.29 ± 3.512.24 ± 3.522.32 ± 3.862.48 ± 3.92
Week 6 (N= 899, 893, 909, 897)2.23 ± 3.562.18 ± 3.572.40 ± 3.872.48 ± 3.97
Week 8 (N= 868, 861, 877, 877)2.17 ± 3.602.16 ± 3.702.28 ± 3.602.64 ± 4.29
Week 10 (N= 853, 844, 852, 846)2.29 ± 3.891.96 ± 3.242.33 ± 3.802.57 ± 4.41
Week 12 (N= 772, 768, 750, 742)2.07 ± 3.481.83 ± 3.212.01 ± 3.512.46 ± 4.10
Week 13 (N= 797, 796, 789, 807)2.11 ± 3.741.85 ± 3.222.01 ± 3.472.38 ± 4.27
Week 16 (N= 784, 797, 775, 789)2.05 ± 3.471.90 ± 3.432.09 ± 3.612.34 ± 3.98
Week 20 (N= 771, 785, 762, 772)2.10 ± 3.541.93 ± 3.361.97 ± 3.532.31 ± 4.15
Week 24 (N= 758, 748, 737, 758)2.01 ± 3.491.87 ± 3.472.01 ± 3.452.25 ± 4.04
SecondaryHADS Total Score, Psychiatric History Cohort

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
HADS Total Score, Psychiatric History Cohort
Units on a scaleVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Week 1 (N= 1026, 1017, 1015, 1015)6.76 ± 6.147.58 ± 6.876.82 ± 6.336.70 ± 5.94
Week 2 (N= 1005, 1004, 996, 995)6.42 ± 6.366.99 ± 6.476.64 ± 6.556.42 ± 6.17
Week 3 (N= 947, 961, 945, 926)5.99 ± 6.216.51 ± 6.396.30 ± 6.556.02 ± 6.10
Week 4 (N= 935, 938, 929, 908)5.87 ± 6.396.36 ± 6.556.16 ± 6.516.04 ± 6.31
Week 5 (N= 918, 918, 914, 895)5.58 ± 6.326.03 ± 6.415.82 ± 6.445.80 ± 6.31
Week 6 (N= 917, 914, 912, 874)5.39 ± 6.145.87 ± 6.415.62 ± 6.225.75 ± 6.26
Week 8 (N= 887, 893, 878, 859)5.43 ± 6.245.96 ± 6.685.63 ± 6.365.63 ± 6.26
Week 10 (N= 864, 865, 864, 823)5.38 ± 6.355.72 ± 6.505.64 ± 6.305.55 ± 6.38
Week 12 (N= 790, 803, 798, 749)5.17 ± 6.095.66 ± 6.635.44 ± 6.305.42 ± 6.13
Week 13 (N= 813, 812, 814, 763)5.06 ± 6.115.44 ± 6.545.36 ± 6.205.09 ± 5.96
Week 16 (N= 795, 805, 791, 748)5.26 ± 6.355.62 ± 6.685.44 ± 6.345.37 ± 6.38
Week 20 (N= 784, 784, 763, 737)5.17 ± 6.025.54 ± 6.445.46 ± 6.185.26 ± 6.22
Week 24 (N= 770, 764, 758, 729)5.21 ± 6.275.69 ± 6.645.57 ± 6.325.04 ± 5.97
SecondaryHADS Total Score (Overall)

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
HADS Total Score (Overall)
Units on a scaleVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Week 1 (N= 1989, 1976, 1985, 1987)5.03 ± 5.455.61 ± 6.074.95 ± 5.585.05 ± 5.41
Week 2 (N= 1938, 1937, 1931, 1929)4.68 ± 5.555.06 ± 5.734.74 ± 5.704.80 ± 5.53
Week 3 (N= 1882, 1891, 1881, 1867)4.31 ± 5.444.60 ± 5.634.48 ± 5.714.38 ± 5.37
Week 4 (N= 1858, 1854, 1863, 1831)4.15 ± 5.504.39 ± 5.654.31 ± 5.644.39 ± 5.60
Week 5 (N= 1829, 1815, 1820, 1797)3.94 ± 5.374.16 ± 5.524.08 ± 5.594.14 ± 5.51
Week 6 (N= 1816, 1807, 1821, 1771)3.82 ± 5.274.05 ± 5.524.01 ± 5.424.09 ± 5.48
Week 8 (N= 1755, 1754, 1755, 1736)3.82 ± 5.364.10 ± 5.753.96 ± 5.434.12 ± 5.56
Week 10 (N= 1717, 1709, 1716, 1669)3.85 ± 5.493.86 ± 5.484.00 ± 5.474.04 ± 5.67
Week 12 (N= 1562, 1571, 1548, 1491)3.64 ± 5.213.79 ± 5.583.78 ± 5.423.95 ± 5.42
Week 13 (N= 1610, 1608, 1603, 1570)3.60 ± 5.293.66 ± 5.473.71 ± 5.323.70 ± 5.34
Week 16 (N= 1579, 1602, 1566, 1537)3.67 ± 5.373.77 ± 5.633.78 ± 5.443.82 ± 5.50
Week 20 (N= 1555, 1569, 1525, 1509)3.65 ± 5.183.73 ± 5.443.72 ± 5.333.75 ± 5.47
Week 24 (N= 1528, 1512, 1495, 1487)3.62 ± 5.333.80 ± 5.643.82 ± 5.413.62 ± 5.27
SecondaryPositive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Non-psychiatric History Cohort

The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.

Time frame:
Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants with positive responses
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Non-psychiatric History Cohort
participants with positive responsesVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Suicidal Behavior (Screening lifetime)6976
Suicidal Ideation (Screening lifetime)48435049
Suicidal Behavior (Baseline)0000
Suicidal Ideation (Baseline)0101
Suicidal Behavior (treatment emergent 12 weeks)0011
Suicidal Ideation (treatment emergent 12 weeks)7436
SecondaryPositive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Psychiatric History Cohort

The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.

Time frame:
Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants with positive responses
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Psychiatric History Cohort
participants with positive responsesVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Suicidal Behavior (Screening lifetime)137143111123
Suicidal Ideation (Screening lifetime)338357333349
Suicidal Behavior (Baseline)0001
Suicidal Ideation (Baseline)6523
Suicidal Behavior (treatment emergent 12 weeks)0102
Suicidal Ideation (treatment emergent 12 weeks)27152025
SecondaryPositive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Overall

The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.

Time frame:
Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Reported as:
Number · participants with positive responses
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Overall
participants with positive responsesVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Suicidal Behavior (Screening lifetime)143152118129
Suicidal Ideation (Screening lifetime)386400383398
Suicidal Behavior (Baseline)0001
Suicidal Ideation (Baseline)6624
Suicidal Behavior (treatment emergent 12 weeks)0113
Suicidal Ideation (treatment emergent 12 weeks)34192331
SecondaryClinical Global Impression of Improvement (CGI-I), "No Change" Rating by Visit

The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as "normal, not at all ill" on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as "no change" on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Clinical Global Impression of Improvement (CGI-I), "No Change" Rating by Visit
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Week 1 (N= 1986, 1974, 1986, 1982)94.293.294.695.1
Week 2 (N= 1934, 1936, 1927, 1926)90.890.890.591.2
Week 3 (N= 1880, 1892, 1880, 1863)88.389.888.787.9
Week 4 (N= 1860, 1856, 1858, 1834)86.688.087.186.3
Week 5 (N= 1828, 1816, 1822, 1802)85.786.585.585.4
Week 6 (N= 1816, 1808, 1820, 1773)85.286.585.184.1
Week 8 (N= 1758, 1756, 1755, 1738)82.483.682.881.9
Week 10 (N= 1717, 1707, 1715, 1675)80.681.780.479.2
Week 12 (N= 1558, 1572, 1540, 1492)72.975.172.271.3
Week 13 (N= 1612, 16081602, 1575)75.976.775.274.9
Week 16 (N= 1586, 1606, 1568, 1541)74.276.773.973.4
Week 20 (N= 1563, 1573, 1523, 1510)73.475.072.271.7
Week 24 (N= 1533, 1515, 1499, 1497)71.872.371.171.1
SecondaryCO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort

A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).

Time frame:
Week 9 through Week 12
Reported as:
Number · percentage of participants
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort38.026.126.413.7
Statistical analysis
  • Varenicline 1.0 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 4.00 · 95% CI 3.20 to 5.00
  • Bupropion 150 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.26 · 95% CI 1.80 to 2.85
  • NRT Patch vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.30 · 95% CI 1.83 to 2.90
SecondaryCO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort

A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).

Time frame:
Week 9 through Week 12
Reported as:
Number · percentage of participants
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort29.219.320.411.4
Statistical analysis
  • Varenicline 1.0 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 3.24 · 95% CI 2.56 to 4.11
  • Bupropion 150 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 1.87 · 95% CI 1.46 to 2.39
  • NRT Patch vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.00 · 95% CI 1.56 to 2.55
SecondaryCO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)

A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).

Time frame:
Week 9 through Week 12
Reported as:
Number · percentage of participants
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)33.522.623.412.5
Statistical analysis
  • Varenicline 1.0 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 3.61 · 95% CI 3.07 to 4.24
  • Bupropion 150 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.07 · 95% CI 1.75 to 2.45
  • NRT Patch vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.15 · 95% CI 1.82 to 2.54
SecondaryCO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort

A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).

Time frame:
Week 9 through Week 24
Reported as:
Number · percentage of participants
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort25.518.818.510.5
Statistical analysis
  • Varenicline 1.0 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.99 · 95% CI 2.33 to 3.83
  • Bupropion 150 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.00 · 95% CI 1.54 to 2.59
  • NRT Patch vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 1.96 · 95% CI 1.51 to 2.54
SecondaryCO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort

A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).

Time frame:
Week 9 through Week 24
Reported as:
Number · percentage of participants
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort18.313.713.08.3
Statistical analysis
  • Varenicline 1.0 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.50 · 95% CI 1.90 to 3.29
  • Bupropion 150 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 1.77 · 95% CI 1.33 to 2.36
  • NRT Patch vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 1.65 · 95% CI 1.24 to 2.20
SecondaryCO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)

A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).

Time frame:
Week 9 through Week 24
Reported as:
Number · percentage of participants
CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)21.816.215.79.4
Statistical analysis
  • Varenicline 1.0 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 2.74 · 95% CI 2.28 to 3.30
  • Bupropion 150 mg BID vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 1.89 · 95% CI 1.56 to 2.29
  • NRT Patch vs Placebo · Regression, Logistic · p = <0.0001 (No multiplicity adjustment.) · Odds ratio (or): 1.81 · 95% CI 1.49 to 2.19
Secondary7-Day Point Prevalence of Abstinence, Non-psychiatric History Cohort

A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?

Time frame:
24 Weeks
Reported as:
Number · percentage of participants
7-Day Point Prevalence of Abstinence, Non-psychiatric History Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Week 11.71.01.21.5
Week 220.921.315.511.4
Week 330.026.622.113.6
Week 434.327.725.914.5
Week 538.429.827.814.9
Week 641.031.430.415.9
Week 744.435.235.119.2
Week 842.331.031.416.7
Week 947.134.934.819.0
Week 1042.431.031.116.9
Week 1146.634.134.920.8
Week 1244.430.530.417.8
Week 1341.130.729.917.2
Week 1444.533.532.020.4
Week 1543.833.232.421.3
Week 1637.228.528.118.2
Week 1740.731.931.420.1
Week 1840.931.331.720.8
Week 1939.931.231.220.8
Week 2035.127.526.318.2
Week 2138.130.329.320.1
Week 2238.729.929.020.3
Week 2337.630.628.320.3
Week 2433.626.027.017.4
Secondary7-Day Point Prevalence of Abstinence, Psychiatric History Cohort

A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?

Time frame:
24 Weeks
Reported as:
Number · percentage of participants
7-Day Point Prevalence of Abstinence, Psychiatric History Cohort
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Week 11.01.20.70.5
Week 216.814.613.09.2
Week 322.718.117.910.7
Week 426.621.321.111.8
Week 528.521.822.412.4
Week 630.822.723.313.4
Week 734.825.427.516.6
Week 832.722.124.615.0
Week 936.226.029.417.2
Week 1035.124.325.014.0
Week 1138.627.429.417.2
Week 1235.023.924.914.2
Week 1332.722.624.014.8
Week 1434.725.026.817.8
Week 1533.425.326.018.3
Week 1629.121.921.813.9
Week 1732.324.024.817.4
Week 1831.724.524.718.2
Week 1931.624.725.117.6
Week 2026.620.425.117.6
Week 2129.723.223.717.5
Week 2229.122.923.616.5
Week 2328.523.522.216.4
Week 2426.120.420.114.0
Secondary7-Day Point Prevalence of Abstinence (Overall)

A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?

Time frame:
24 Weeks
Reported as:
Number · percentage of participants
7-Day Point Prevalence of Abstinence (Overall)
percentage of participantsVarenicline 1.0 mg BIDBupropion 150 mg BIDNRT PatchPlacebo
Week 11.31.10.91.0
Week 218.817.914.210.3
Week 326.322.320.012.1
Week 430.424.423.513.1
Week 533.425.725.113.6
Week 635.826.926.814.6
Week 739.530.231.317.9
Week 837.426.528.015.9
Week 941.630.432.118.1
Week 1038.727.628.015.5
Week 1142.530.732.118.8
Week 1239.627.127.616.0
Week 1336.826.526.916.0
Week 1439.529.229.419.1
Week 1538.529.229.219.8
Week 1633.125.124.916.1
Week 1736.427.928.118.8
Week 1836.227.828.219.5
Week 1935.727.928.119.2
Week 2030.823.923.716.3
Week 2133.926.726.518.8
Week 2233.826.426.318.4
Week 2333.027.025.318.3
Week 2429.823.223.615.7

Adverse events

Collected over From baseline throughout the study period (16 weeks). Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline 1.0 mg BID—39/2,016 (1.9%)1,158/2,016 (57.4%)
Bupropion—48/2,006 (2.4%)1,033/2,006 (51.5%)
NRT Patch—45/2,022 (2.2%)1,003/2,022 (49.6%)
Placebo—41/2,014 (2%)884/2,014 (43.9%)
Most frequent serious events
Showing 10 of 142
Most frequent serious events
EventVarenicline 1.0 mg BIDBupropionNRT PatchPlacebo
Atrial fibrillationCardiac disorders0/20161/20064/20220/2014
Chest painGeneral disorders1/20160/20064/20222/2014
AlcoholismPsychiatric disorders0/20163/20061/20220/2014
Suicidal ideationPsychiatric disorders2/20161/20060/20223/2014
Suicide attemptPsychiatric disorders0/20162/20061/20221/2014
Non-cardiac chest painGeneral disorders0/20162/20061/20221/2014
Bipolar I disorderPsychiatric disorders1/20162/20060/20220/2014
AngioedemaSkin and subcutaneous tissue disorders0/20162/20060/20220/2014
Cardiac failure congestiveCardiac disorders0/20160/20060/20222/2014
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/20160/20060/20222/2014
Most frequent other events
Showing 10 of 11
Most frequent other events
EventVarenicline 1.0 mg BIDBupropionNRT PatchPlacebo
NauseaGastrointestinal disorders511/2016201/2006199/2022137/2014
Abnormal dreamsPsychiatric disorders201/2016131/2006251/202292/2014
InsomniaPsychiatric disorders189/2016245/2006195/2022139/2014
HeadacheNervous system disorders245/2016186/2006233/2022199/2014
NasopharyngitisInfections and infestations174/2016156/2006126/2022135/2014
AnxietyPsychiatric disorders132/2016169/2006137/2022120/2014
Dry mouthGastrointestinal disorders66/2016146/200659/202264/2014
FatigueGeneral disorders124/201657/200675/202283/2014
Upper respiratory tract infectionInfections and infestations109/2016104/200697/2022115/2014
Application site pruritusGeneral disorders22/201612/2006109/202216/2014

Baseline characteristics

The safety analysis population contained all treated participants i.e. who received at least one partial dose of study medication.

Age, Continuous
Age, Continuous(Years)Varenicline 1.0 mg BIDBupropionNRT PatchPlaceboTotal
Mean46.5 ± 12.446.3 ± 12.646.8 ± 12.246.4 ± 12.246.5 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Varenicline 1.0 mg BIDBupropionNRT PatchPlaceboTotal
Female11141116114111384509
Male9028908818763549
08

Study locations

156 sites
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • NoesisPharma Research
    Phoenix, Arizona 85032, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Synergy Clinical Research of Escondido
    Escondido, California 92025, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Omega Clinical Trials
    La Habra, California 90631, United States
  • Pacific Treatment and Research Center UC San Diego Health System
    La Jolla, California 92037, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • David Geffen School of Medicine at University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • North County Clinical Research
    Oceanside, California 92056, United States
  • Neuropsychiatric Research Center of Orange County
    Orange, California 92868, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • University of Colorado Denver, Anschutz Medical Campus , Behavioral Health and Wellness Program
    Aurora, Colorado 80045, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80209, United States
  • Comprehensive Psychiatric Care
    Norwich, Connecticut 06360, United States
  • Neuropsychiatric Research Center of Southwest Florida
    Fort Myers, Florida 33912, United States
  • Broward Research Group
    Hollywood, Florida 33024, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Clinical Neuroscience Solutions,Inc.
    Jacksonville, Florida 32256, United States
  • Meridien Research
    Lakeland, Florida 33805, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Ocala Psychiatric Associates
    Ocala, Florida 34474, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32801, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Northwest Neurobehavioral Health
    Meridian, Idaho 83642, United States
  • AMR-Baber Research Inc.
    Naperville, Illinois 60563, United States
  • American Health Network of IN, LLC
    Indianaopolis, Indiana 46254, United States
  • Davis Clinic, Incorporated
    Indianapolis, Indiana 46250, United States
  • Goldpoint Clinical Research, LLC
    Indianapolis, Indiana 46260, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Kentucky Research Group
    Louisville, Kentucky 40218, United States
  • A Professional Corporation dba The Center for Sexual Health
    Metairie, Louisiana 70002, United States
  • Maine Research Associates
    Auburn, Maine 04210, United States
  • Community Clinical Services
    Lewiston, Maine 04240, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Milford Emergency Associates, Incorporated
    Milford, Massachusetts 01757, United States
  • Rahim Shafa, MD
    Milford, Massachusetts 01757, United States
  • University of Minnesota- TC
    Minneapolis, Minnesota 55414, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • The Center for Pharmaceutical Research, PC
    Kansas City, Missouri 64114, United States
  • Mercy Health Research
    St.Louis, Missouri 63141, United States
  • University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Global Medical Institutes LLC; Princeton Medical Institute Woodlands Professional Building
    Princeton, New Jersey 08540, United States
  • Social Psychiatry Research Institute Clinical Trials LLC
    Brooklyn, New York 11235, United States
  • Regional Clinical Research, Inc.
    Endwell, New York 13760, United States
  • Tooley Group
    Cary, North Carolina 27511, United States
  • PMG Research of Raleigh, LLC d/b/a PMG Research of Cary
    Cary, North Carolina 27518, United States
  • Wake Internal Medicine Consultants, Inc
    Raleigh, North Carolina 27612, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239-3098, United States
  • Southeastern PA Medical Institute
    Broomall, Pennsylvania 19008, United States
  • Belmont Center for Comprehensive Treatment
    Philadelphia, Pennsylvania 19131, United States
  • CRI Worldwide, LLC
    Philadelphia, Pennsylvania 19139, United States
  • East Side Clinical Laboratory
    Lincoln, Rhode Island 02865, United States
  • Lincoln Research
    Lincoln, Rhode Island 02865, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Clinical NeuroScience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • James G. Kyser, MD
    Nashville, Tennessee 37203, United States
  • FutureSearch Clinical Trials, L.P.
    Austin, Texas 78731, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77230-1439, United States
  • Peninsula Psychotherapy Center, LLC
    Newport News, Virginia 23606, United States
  • Clinical Research Associates of Tidewater
    Norfolk, Virginia 23507, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53711-2027, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • Centro Medico Dra. De Salvo
    Ciudad Autonoma de Bs. As, Buenos Aires C1426ABP, Argentina
  • Centro de Investigacion Clinica WM
    Mataderos, Buenos Aires C1440BRR, Argentina
  • Royal Brisbane & Women's Hospital
    Herston, Queensland 4029, Australia
  • Monash Alfred Psychiatry Research Centre
    Melbourne, Victoria 3004, Australia
  • Hospital de Messejana Dr. Carlos Alberto Studart Gomes
    Fortaleza, CE 60846-190, Brazil
  • Irmandade da Santa Casa de Misericórdia Porto Alegre
    Porto Alegre, RS 90035-074, Brazil
  • Hospital Sao Lucas da PUCRS - Uniao Brasileira de Educacao e Assistencia
    Porto Alegre, RS 90610-000, Brazil
  • Hospital e Maternidade Celso Pierro - Pontifícia Universidade Católica de Campinas - Campus II
    Campinas, SP 13059-740, Brazil
  • Instituto Jaqueline Scholz Issa e Mario Issa de cardiologia S/C Ltda
    Sao Paulo, SP 05017-000, Brazil
  • Mental Health Center "Prof. Dr. Ivan Temkov-Bourgas" Ltd.
    Bourgas, 8000, Bulgaria
  • MBAL Dr. Hristo Stambolski EOOD
    Kazanlak, 6100, Bulgaria
  • DPB Sv. Ivan Rilski
    Novi Iskar, 1282, Bulgaria
  • UMBAL Dr. Georgi Stranski EAD,
    Pleven, 5800, Bulgaria
  • UMBAL Sveti Georgi EAD, Klinika po psihiatriya
    Plovdiv, 4002, Bulgaria
  • SBALPFZ - Ruse EOOD
    Ruse, 7002, Bulgaria
  • Tsentar za psihichno zdrave - Ruse EOOD
    Ruse, 7004, Bulgaria
  • Meditsinski Tsentar ¿Sveti Naum¿ EOOD
    Sofia, 1113, Bulgaria
  • MHATNP Sveti Naum SJsc.
    Sofia, 1113, Bulgaria
  • Specializirana Bolnitsa za Aktivno Lechenie na Belodrobni Bolesti-Troyan EOOD,
    Troyan, 5600, Bulgaria
  • Hamilton Medical Research Group
    Hamilton, Ontario L8M 1K7, Canada
  • Medical Research Associates
    Mississauga, Ontario L5M 4N4, Canada
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3J 2C5, Canada

Showing the first 100 of 156 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tonnesen P, Lawrence D, Tonstad S. Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial. Tob Induc Dis. 2022 May 10;20:46. doi: 10.18332/tid/146567. eCollection 2022. PubMed 35611069 ↗
  • Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, Minnix J, Blalock JA, Beneventi D, Morris C, Karam-Hage M. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety. 2022 May;39(5):429-440. doi: 10.1002/da.23259. PubMed 35535436 ↗
  • Ebbert JO, Jimenez-Ruiz C, Dutro MP, Fisher M, Li J, Hays JT. In Reply: Changing the Culture of Tobacco Dependence Treatment Among Not Only Patients, But Also Prescribers. Mayo Clin Proc. 2021 Sep;96(9):2495. doi: 10.1016/j.mayocp.2021.07.010. No abstract available. PubMed 34481605 ↗
  • Ebbert J, Jimenez-Ruiz C, Dutro MP, Fisher M, Li J, Hays JT. Frequently Reported Adverse Events With Smoking Cessation Medications: Post Hoc Analysis of a Randomized Trial. Mayo Clin Proc. 2021 Jul;96(7):1801-1811. doi: 10.1016/j.mayocp.2020.10.046. Epub 2021 Jun 8. PubMed 34112520 ↗
  • Beard E, Jackson SE, Anthenelli RM, Benowitz NL, Aubin LS, McRae T, Lawrence D, Russ C, Krishen A, Evins AE, West R. Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. Addiction. 2021 Oct;116(10):2816-2824. doi: 10.1111/add.15440. Epub 2021 Apr 22. PubMed 33885203 ↗
  • Correa JB, Lawrence D, McKenna BS, Gaznick N, Saccone PA, Dubrava S, Doran N, Anthenelli RM. Psychiatric Comorbidity and Multimorbidity in the EAGLES Trial: Descriptive Correlates and Associations With Neuropsychiatric Adverse Events, Treatment Adherence, and Smoking Cessation. Nicotine Tob Res. 2021 Aug 29;23(10):1646-1655. doi: 10.1093/ntr/ntab056. PubMed 33788933 ↗
  • Nollen NL, Ahluwalia JS, Sanderson Cox L, Okuyemi K, Lawrence D, Samuels L, Benowitz NL. Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation: Secondary Analysis of the EAGLES Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2032053. doi: 10.1001/jamanetworkopen.2020.32053. PubMed 33464316 ↗
  • Evins AE, West R, Benowitz NL, Russ C, Lawrence D, McRae T, Maravic MC, Heffner JL, Anthenelli RM. Efficacy and Safety of Pharmacotherapeutic Smoking Cessation Aids in Schizophrenia Spectrum Disorders: Subgroup Analysis of EAGLES. Psychiatr Serv. 2021 Jan 1;72(1):7-15. doi: 10.1176/appi.ps.202000032. Epub 2020 Nov 3. PubMed 33138708 ↗
  • Ayers CR, Heffner JL, Russ C, Lawrence D, McRae T, Evins AE, Anthenelli RM. Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. Depress Anxiety. 2020 Mar;37(3):247-260. doi: 10.1002/da.22982. Epub 2019 Dec 18. PubMed 31850603 ↗
  • Heffner JL, Evins AE, Russ C, Lawrence D, Ayers CR, McRae T, Aubin LS, Krishen A, West R, Anthenelli RM. Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial. J Affect Disord. 2019 Sep 1;256:267-277. doi: 10.1016/j.jad.2019.06.008. Epub 2019 Jun 3. PubMed 31195244 ↗
  • Anthenelli RM, Gaffney M, Benowitz NL, West R, McRae T, Russ C, Lawrence D, St Aubin L, Krishen A, Evins AE. Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial. J Gen Intern Med. 2019 Jun;34(6):862-870. doi: 10.1007/s11606-019-04858-2. Epub 2019 Mar 7. PubMed 30847828 ↗
  • West R, Evins AE, Benowitz NL, Russ C, McRae T, Lawrence D, St Aubin L, Krishen A, Maravic MC, Anthenelli RM. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction. 2018 Aug;113(8):1507-1516. doi: 10.1111/add.14208. Epub 2018 Mar 30. PubMed 29508470 ↗
  • Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016 Jun 18;387(10037):2507-20. doi: 10.1016/S0140-6736(16)30272-0. Epub 2016 Apr 22. PubMed 27116918 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2011
First posted
Oct 21, 2011
Start
Nov 2011
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
May 2, 2016
Last update
Jun 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01456936
Lead sponsor
Pfizer
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 21, 2011
Start date
Nov 2011
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
May 2, 2016
Last update
Jun 10, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Varenicline · Bupropion

Start the discussion